Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that finasteride significantly reduced serum dihydrotestosterone levels, confirming its efficacy as a 5a-reductase inhibitor, while Permixon showed no effect in healthy male volunteers.

This review discusses the biological properties of 18β‐glycyrrhetinic acid derived from licorice root, highlighting its potential anti-inflammatory, antioxidant, and antimicrobial benefits in treating dermatological disorders, and reports no new experimental results.

This study found that 1-year use of 5alpha-reductase inhibitors, dutasteride or finasteride, significantly lowered dihydrotestosterone levels without adversely affecting bone density, lipids, or hemoglobin in normal men.

This review discusses the pathways of androgen biosynthesis and reports no new findings, highlighting the need to understand the interplay between the classic and backdoor pathways.

In this study, Ganoderma lucidum extract was found to significantly inhibit 5alpha-reductase activity and testosterone-induced prostate growth in rats, suggesting potential use for treating benign prostatic hyperplasia.

This study found that the binding of finasteride to the enzyme 5a-reductase occurs at a slower rate than previously assumed, complicating the estimation of its real inhibitory constant.

This study found that untreated men with coeliac disease exhibited androgen resistance, potentially linked to sexual dysfunction, which improved as intestinal health improved, a pattern not observed in other chronic illnesses.

This study engineered a bioluminescent yeast strain responsive to androgenic chemicals, demonstrating rapid and sensitive detection suitable for high-throughput screening and environmental monitoring.

This chapter reviews the role of androgen receptors in mediating the actions of androgens in specific tissues and provides no new experimental findings.

This study suggests that the paradoxical effects of androgens on hair growth are due to differential gene expression in hair follicles, possibly established during embryogenesis.

This review discusses the role of anti-androgen therapies in cancer and other diseases and reports no new clinical results, highlighting both old and new generations of anti-androgens.

In this study, finasteride doses as low as 0.2 mg per day significantly reduced both scalp skin and serum DHT levels in men with androgenetic alopecia.

This study found that men receiving enzalutamide and other androgen-deprivation therapies may be at increased risk for QT prolongation and torsades de pointes.

This review discusses biochemical studies on 5 alpha-reductase and its inhibitors, comparing IC50 and Ki values for various compounds, but reports no new experimental results.

The researchers reported that the petroleum ether extract of Cuscuta reflexa may promote hair growth in testosterone-induced alopecia in mice by inhibiting the enzyme 5α-reductase.

This article reviews the use of finasteride for treating male pattern hair loss, highlighting its mechanism of action in reducing DHT and noting its safety profile with some common adverse effects.

This review describes the shift in treating symptomatic benign prostatic hyperplasia from surgery to 5alpha-reductase inhibitor drugs, which may provide symptom relief and alter BPH's progression, but reports no new clinical results.

This study found that overexpression of Wnt1a in bone marrow mesenchymal stem cells enhanced mouse hair follicle regeneration and promoted hair cycling.

This study found that steroid sulfatase in the dermal papilla of hair follicles metabolizes dehydroepiandrosterone sulfate to support the development of androgenetic alopecia, suggesting potential for steroid sulfatase inhibitors as treatments.

In this study, anabolic and catatoxic steroids were reported to prevent weight loss, tissue calcification, and cardiac necrosis in a rat model of disturbed calcium metabolism and progeria-like syndrome.

Both drugs lower DHT levels, with GI198745 being more effective.

This review discusses current therapeutic targets and treatments for androgenic alopecia but reports no clinical results; the authors highlight the challenge of developing multi-target drugs for effective treatment.

This study suggests that epitestosterone may play a role in regulating androgen-dependent processes like prostate growth and body hair distribution by counteracting testosterone's actions.

Genetics and hormones cause hair loss; finasteride treats it safely.

This study found that 4 weeks of finasteride treatment significantly decreased DHT levels in bald scalp to levels similar to hair-containing scalp in men with male pattern baldness.

This chapter discusses androgen receptors and protein synthesis in the prostate, reporting that DHT-dependent receptor protein translocation increases protein-synthesizing activity after androgen injection in rat models.

Hormones and signaling pathways control sebaceous gland function and could help treat acne.

This study found that testosterone and 5α-dihydrotestosterone induced apoptosis in dermal papilla cells from nonbalding scalp regions, suggesting a high androgen stimulus can trigger cell death related to androgenetic alopecia.

This study found that despite the presence of steroidogenesis inhibitors, CRPC tumor cells adapt to continue synthesizing androgens, suggesting a need for more effective androgen axis targeting.

This review found that women with idiopathic hirsutism may have increased 5α-reductase activity, as indicated by elevated levels of a dihydrotestosterone-reduced metabolite, but more research is needed to confirm its clinical relevance as a biomarker.